Using thyroid hormone to treat liver disease in veterans

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of low dose thyroid hormone in treating nonalcoholic steatohepatitis (NASH) among veterans. The study will involve administering titrated doses of thyroid hormone to participants with biopsy-proven NASH and monitoring for histological improvements in liver condition. The trial is structured in two stages, beginning with a proof of concept followed by an interim analysis to determine if the study should continue. The primary outcome will be assessed through changes in the nonalcoholic fatty liver disease score (NAS).

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women (pre- and post-menopausal)
* Overweight/obese subjects with body mass index (BMI) at or above 25.9 kg/m2
* Alcohol intake \< 20 grams per day
* Patients with type 2 diabetes on stable doses of antidiabetic medication for at least 3 months before enrollment
* Patients who are treated with vitamin E or pioglitazone should be on stable doses for at least 6 months before enrollment
* Features of metabolic syndrome: 3 or more (central obesity, hypertension, low HDL, high triglycerides, high fasting glucose)
* Scheduled for a medically indicated, diagnostic liver biopsy
* Female patients are eligible if they are of reproductive potential and have a negative serum pregnancy test (beta human chorionic gonadotropin), are not breastfeeding, and do not plan to become pregnant during the study and agree to use two highly effective birth control methods during the study OR if they are not of child-bearing potential (i.e., surgically \[bilateral oophorectomy, hysterectomy, or tubal ligation\] or naturally sterile \[\> 12 consecutive months without menses\])

  * Highly effective birth control methods include condoms with spermicide, diaphragm with spermicide, hormonal and nonhormonal intrauterine device, hormonal contraception (estrogens stable for at least 3 months), a vasectomized male partner, or sexual abstinence (defined as refraining from heterosexual intercourse), from screening, throughout the study, and for at least 30 days after the last dose of study drug administration
  * Reliance on abstinence from heterosexual intercourse is acceptable only if it is the patient's habitual practice
* If a patient is on digitalis and amiodarone, he/she is expected to use/continue these medications throughout the treatment period only after consultation with their cardiologist for monitoring and dose adjustments if necessary

Exclusion Criteria:

* Other causes of hepatitis including hepatitis B \& C, autoimmune hepatitis, hemochromatosis, celiac disease, Wilson's disease, alpha-1-antitrypsin deficiency, medication-induced hepatitis
* Alcohol consumption of 20 g/d or more
* Patients with cirrhosis, bilirubin of 1.3 mg/dL or more, and INR of 1.3 or more
* Evidence of Portal hypertension
* Pregnancy
* History of malignant hypertension
* Uncontrolled hypertension (either treated or untreated) defined as systolic blood pressure \> 160 mm Hg or a diastolic blood pressure \> 100 mm Hg at screening
* New York Heart Association Class III or IV heart failure or known left ventricular ejection fraction \< 30%
* Uncontrolled cardiac arrhythmia, including confirmed QT interval corrected using Fridericia's formula (QTcF) \> 450 msec for males and \> 470 msec for females at the screening electrocardiogram (ECG) assessment
* History of myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft, or stroke within at least 3 months prior to randomization
* History of high degree AV block (Mobitz II or complete) in the absence of a pacemaker
* Patients with uncorrected adrenal insufficiency
* Patients who are on tricyclic or tetracyclic antidepressants or ketamine, if they are unwilling and/or unable to discontinue these medications to allow adequate washout prior to randomization
* Patients who are on Teduglutide or Midodrine

Where it's running

• Harry S. Truman Memorial, Columbia, MO
  Columbia, Missouri, United States Recruiting

Study contacts

• Principal investigator: Jamal A Ibdah, MD PhD — Harry S. Truman Memorial, Columbia, MO
• Study coordinator: Adam T Whaley-Connell, DO MSPH
• Email: Adam.Whaley-Connell@va.gov
• Phone: (573) 814-6552

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Endohepatology-based reclassification of treatment indication in high-risk MASLD

  This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.

  Recruiting University Hospital Muenster · Münster · NCT07877272

• Umbilical cord stem cells added during Kasai to help biliary atresia

  This early-stage trial tests whether injecting umbilical cord mesenchymal stem cells during Kasai portoenterostomy is safe and helpful for infants with biliary atresia.

  Recruiting Phase 1 Dr Cipto Mangunkusumo General Hospital · Jakarta Pusat, DKI Jakarta · NCT07797673

• Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD

  This program automatically screens high‑risk adults aged 50–75 in primary care to see if they have advanced liver fibrosis and possible MASLD, using routine blood tests and reflex lab tests without extra work for clinicians.

  Recruiting Hospital General Universitario Gregorio Marañon · Madrid, Madrid · NCT07658755

• AZD2389 safety and dosing in adults with fatty liver disease and advanced liver scarring

  This study tests whether AZD2389 is safe and how it behaves in adults with steatotic liver disease and advanced fibrosis, comparing it to placebo over about six months.

  Recruiting at 22 sites Phase 2 AstraZeneca · Chandler, Arizona and 21 other locations · NCT07610837

• See if EUS-SWQ can accurately detect and grade liver fibrosis in adults with chronic liver disease

  This study tests whether the endoscopic ultrasound shear wave quantification (EUS-SWQ) can match liver biopsy results in adults with chronic liver disease to diagnose and stage fibrosis, and whether it offers safety and measurement advantages over FibroScan.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07588854

• Tesamorelin to reduce liver fat in adults with fatty liver disease

  This trial tests whether a daily self‑injection of tesamorelin can lower liver fat over 52 weeks in adults with fatty liver disease.

  Recruiting Phase 2 Hudson Biotech · Shenzhen, Guangdong · NCT07481734

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.